Reports Q2 revenue $1.278B, consensus $1.26B. “Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world,” said Brent Saunders, chairman and CEO, Bausch + Lomb (BLCO). “Our robust pipeline represents the future of the company, and we’re excited to showcase potential gamechangers at our November 13 investor day.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops
- Bausch + Lomb publishes Lumify eye drops data in Ophthalmology and Therapy
- Bausch + Lomb Amends CEO Employment Agreement
- Bausch + Lomb price target raised to $15 from $13 at Citi
- Mixed Product Performance and Market Challenges Justify Hold Rating for Bausch + Lomb